Agilent Technologies Inc. (NYSE: A) today announced the introduction of its Dako Omnis family of instruments with three new models—Agilent Dako Omnis 110, 165, and 165 Duo—designed to meet the evolving needs of pathology laboratories of all sizes. These new instruments provide labs with the flexibility to tailor their staining solutions according to volume, workflow, and diagnostic requirements.

With the launch of the Agilent Dako Omnis family, Agilent transitions beyond a one-size-fits-all model to offer a tailored portfolio—empowering labs to select the configuration that best meets their needs.

Scalable Solutions for Every Lab—From Routine to Revolutionary.

• Dako Omnis 110: Built for precision in low-medium volume labs, delivering up to 110 IHC slides per day with dependable performance.
• Dako Omnis 165: Engineered for efficiency in medium-high volume labs, delivering up to 165 IHC slides per day with seamless consistency.
• Dako Omnis 165 Duo: Designed for ultimate flexibility in medium-high volume labs, delivering simultaneous IHC and ISH with maximum throughput and confidence.

Building on the success of the original Dako Omnis, all models feature continuous, case-based processing and shared reagents, enabling labs to streamline workflows and reduce turnaround times. A newly integrated direct connection for de-ionized water and non-hazardous waste further reduces handling time.

During the testing of the new instruments, Jessica Barbour, senior biomedical scientist at Aberdeen Royal Infirmary, stated, “The addition of the direct connection is beneficial, provided there is access to direct deionized water. It is also advantageous to be able to empty the waste while the machine is operational. In the past, there have been instances where non-hazardous waste was not emptied in the morning, which consequently limited the number of slides we could run throughout the day.”

Majken Nielsen, associate vice president of marketing and product management in the Clinical Diagnostics Division at Agilent, commented on the importance of this launch: “We recognize that pathology labs are under increasing pressure from rising test volumes, limited staffing, and growing diagnostic complexity. This solution was developed in direct response to those challenges. Built on customer feedback, these instruments are designed to simplify workflows, enhance diagnostic efficiency, and help labs deliver timely, high-quality results.”

The new Agilent Dako Omnis family of instruments will debut at major industry events, including the European Congress of Pathology (ECP) from September 6–10, and the National Society for Histotechnology (NSH) from September 26–30. Initial availability will be to the U.S., Europe, and Australia. This launch reinforces Agilent’s commitment to delivering customized, scalable solutions that support diagnostic excellence and long-term lab growth.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250804514299/en/